Latest Posts
Draft guidance seeks to make drug labels clear, concise, more consistent
July 11, 2018 By Wolters Kluwer Contributor
In an effort to assist applicants in writing the Indications and Usage section of labeling for human prescription drug and biological products, the FDA issued a new draft guidance. The FDA’s intent is to make information in prescription drug labeling … [Read More...]
Kusserow on Compliance: OIG Attorneys continue cross-designation with DOJ
July 9, 2018 By Richard Kusserow
The HHS OIG issued its Semi-Annual Report for the first half of fiscal year (FY) 2018 (October-March) and summarizes key accomplishments, significant problems, abuses, deficiencies, and investigative outcomes relating to the administration of HHS … [Read More...]
Kusserow on Compliance: OIG testifies on investigative results over last three years
July 2, 2018 By Richard Kusserow
Gary Cantrell, HHS OIG Deputy Inspector General for Investigations, testified before a Senate Special Committee hearing to highlight the results of the OIG’s enforcement activities, focusing many of his comments on the current Opiod Crisis. He noted … [Read More...]
Recently on Law & Health
- Draft guidance seeks to make drug labels clear, concise, more consistent
- Kusserow on Compliance: OIG Attorneys continue cross-designation with DOJ
- Kusserow on Compliance: OIG testifies on investigative results over last three years
- Kusserow on Compliance: OIG Work Plan items for May 2018
- No abuse of discretion pill mill trial procedure, sentencing vacated and remanded
- Kusserow on Compliance: DOJ ‘Brand’ memorandum
- Kusserow on Compliance: OIG cases involving sanctioned parties and tips to avoid violations
- Kusserow on Compliance: OIG testimony highlights opioid crisis actions
- CBO projects federal subsidies for health insurance coverage
- Kusserow on Compliance: Three new projects added to the OIG Work Plan in April
Cheetah Log In
Law & Health on LinkedIn
